Skip to main content
. 2020 Sep 1;28(4):331–344. doi: 10.3727/096504020X15825405463920

Figure 3.

Figure 3

APG-2575 exhibits antitumor activity in DLBCL xenograft models with BCL-2 overexpression. (a) Tumor volumes of OCI-LY8 xenograft models treated with vehicle or APG-2575 (25, 50, and 100 mg/kg). Data are shown as mean ± standard error of the mean (SEM) of six mice in each group. Statistical significance was determined by two-way ANOVA. **p < 0.01, ***p < 0.001. (b) Tumor weight of the four separate groups was recorded at the end of experiment. Data are shown as mean ± SD of six mice in each group. Statistical significance was determined by one-way ANOVA. **p < 0.01, ***p < 0.001. (c) Photographs of harvested tumors of OCI-LY8 tumor-bearing mice. (d) Mice weight of four separate groups was recorded. Data are shown as mean ± SD of six mice in each group. (e) Representative photomicrographs of TUNEL-positive cells and DAPI in xenograft tumors from four separate groups of mice. All images were collected at the same magnification. (f) The mean percentage of TUNEL-positive cells for four groups treated with vehicle, APG-2575 (20 mg/kg), APG-2575 (50 mg/kg), and APG-2575 (100 mg/kg) from three microscopic fields. The data are plotted as mean ± SD. ***p < 0.001. (g) Western blot analysis of BCL-2, PARP/cleaved PARP, and cleaved caspase 3 protein expression in OCI-LY8 xenograft tumors.